Investigating Reports of Complex Regional Pain Syndrome: An Analysis of HPV-16/18-Adjuvanted Vaccine Post-Licensure Data

EBioMedicine

Volumn 2, Issue 9, 2015, Pages 1114-1121

  Huygen, Frank ^a   Verschueren, Kristin ^b   McCabe, Candida ^c,d   Stegmann, Jens Ulrich ^b   Zima, Julia ^b   Mahaux, Olivia ^b   Van Holle, Lionel ^b   Angelo, Maria Genalin ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b GSK   (Belgium)

^c ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^d UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

Author keywords

Chronic pain; Complex regional pain syndrome; Human papillomavirus vaccine; Safety

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COMPLEX REGIONAL PAIN SYNDROME; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; HYPESTHESIA; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RISK FACTOR; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; VACCINATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; CHRONIC PAIN; DOSE RESPONSE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOLOGY; LICENSING;

ADJUVANTS, IMMUNOLOGIC; CHRONIC PAIN; CLINICAL TRIALS AS TOPIC; COMPLEX REGIONAL PAIN SYNDROMES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LICENSURE; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 84953741602     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.07.003     Document Type: Article

References (39)

1. Angelo M.-G., Zima J., Tavares Da Silva F., Baril L., Arellano F. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4years of experience. Pharmacoepidemiol Drug Saf 2014, 23:456-465.
2. Angelo M.-G., David M.-P., Zima J., et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf 2014, 23:466-479.
3. De Mos M., de Bruijn A.G.J., Huygen F.J.P.M., Dieleman J.P., Stricker B.H.C., Sturkenboom M.C.J.M. The incidence of complex regional pain syndrome: a population-based study. Pain 2007, 129:12-20.
4. De Rooij A.M., Florencia Gosso M., Haasnoot G.W., et al. HLA-B62 and HLA-DQ8 are associated with complex regional pain syndrome with fixed dystonia. Pain 2009, 145:82-85.
5. De Rooij A.M., de Mos M., van Hilten J.J., et al. Increased risk of complex regional pain syndrome in siblings of patients?. J Pain Off J Am Pain Soc 2009, 10:1250-1255.
6. Dirckx M., Schreurs M.W.J., de Mos M., Stronks D.L., Huygen F.J.P.M. The prevalence of autoantibodies in complex regional pain syndrome type I. Mediators Inflamm 2015, 2015:718201.
7. Eberth J.M., Kline K.N., Moskowitz D.A., Montealegre J.R., Scheurer M.E. The role of media and the Internet on vaccine adverse event reporting: a case study of human papillomavirus vaccination. J Adolesc Health Off Publ Soc Adolesc Med 2014, 54:289-295.
8. EMA European Medicines Agency PRAC recommendations on signals adopted at the PRAC meeting of 7-10 April 2014 2014, Pharmacovigilance Risk Assessment Committee.
9. Genc H., Karagoz A., Saracoglu M., Sert E., Erdem H.R. Complex regional pain syndrome type-I after rubella vaccine. Eur J Pain Lond Engl 2005, 9:517-520.
10. Global Advisory Committee on Vaccine Safety Relevé Épidémiologique Hebd Sect Hygiène Secrétariat Société Nations Wkly Epidemiol Rec Health Sect Secr Leag Nations 2013, 88:301-312. (12-13 June).
11. Goebel A., Blaes F. Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. Autoimmun Rev 2013, 12:682-686.
12. Goebel A., Vogel H., Caneris O., et al. Immune responses to campylobacter and serum autoantibodies in patients with complex regional pain syndrome. J Neuroimmunol 2005, 162:184-189.
13. Harden R.N., Bruehl S., Galer B.S., et al. Complex regional pain syndrome: are the IASP diagnostic criteria valid and sufficiently comprehensive?. Pain 1999, 83:211-219.
14. Harden R.N., Bruehl S., Stanton-Hicks M., Wilson P.R. Proposed new diagnostic criteria for complex regional pain syndrome. Pain Med Malden Mass 2007, 8:326-331.
15. Harden R.N., Bruehl S., Perez R.S.G.M., et al. Validation of proposed diagnostic criteria (the 'Budapest criteria') for complex regional pain syndrome. Pain 2010, 150:268-274.
16. Hühne K., Leis S., Schmelz M., Rautenstrauss B., Birklein F. A polymorphic locus in the intron 16 of the human angiotensin-converting enzyme (ACE) gene is not correlated with complex regional pain syndrome I (CRPS I). Eur J Pain Lond Engl 2004, 8:221-225.
17. Jastaniah W.A., Dobson S., Lugsdin J.G., Petty R.E. Complex regional pain syndrome after hepatitis B vaccine. J Pediatr 2003, 143:802-804.
18. Karimi G., Star K., Hägg S., Norén G.N. Time-to-onset in spontaneous reports: the possibility to detect the unexpected. Pharmacoepidemiol Drug Saf 2013, 22:556-557.
19. Kemler M.A., van de Vusse A.C., van den Berg-Loonen E.M., Barendse G.A., van Kleef M., Weber W.E. HLA-DQ1 associated with reflex sympathetic dystrophy. Neurology 1999, 53:1350-1351.
20. Kimura T., Komatsu T., Hosoda R., Nishiwaki K., Shimida Y. Angiotensin-converting enzyme gene polymorphism in patients with neuropathic pain. Proceedings of the 9th World Congress on Pain 2000, 471-476. IASP Press, Seattle, WA; USA. M. Devor, M. Rowbotham, Z. Wiesenfeld-Hallin (Eds.).
21. Kinoshita T., Abe R.-T., Hineno A., Tsunekawa K., Nakane S., Ikeda S.-I. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med Tokyo Jpn 2014, 53:2185-2200.
22. Mailis A., Wade J. Profile of Caucasian women with possible genetic predisposition to reflex sympathetic dystrophy: a pilot study. Clin J Pain 1994, 10:210-217.
23. Medical Dictionary for Regulatory Activities published online June 8. http://www.meddra.org/.
24. Medicines and Healthcare products Regulatory Agency (MHRA) MHRA public assessment report Cervarix (HPV vaccine): update on UK safety experience at the end of 4years use in the HPV routine immunisation programme December, (www.mhra.gov.uk, (accessed Jan 17, 2013)). http://www.mhra.gov.uk/PrintPreview/DefaultSplashPP/CON023340?ResultCount=10&DynamicListQuery=&DynamicListSortBy=xCreationDate&DynamicListSortOrder=Desc&DynamicListTitle=&PageNumber=1&Title=Human%20papillomavirus%20(HPV)%20vaccine.
25. Merksey H., Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms 1994, IASP Press, Seattle, WA; USA.
26. Muneshige H., Toda K., Kimura H., Asou T. Does a viral infection cause complex regional pain syndrome?. Acupunct Electrother Res 2003, 28:183-192.
27. Neumann R.A., Aberer E., Stanek G. Evidence for spirochetal origin of Sudeck's atrophy (algodystrophy, reflex sympathetic dystrophy). Arch Orthop Trauma Surg 1989, 108:314-316.
28. Richards S., Chalkiadis G., Lakshman R., Buttery J.P., Crawford N.W. Complex regional pain syndrome following immunisation. Arch Dis Child 2012, 97:913-915.
29. Sandroni P., Benrud-Larson L.M., McClelland R.L., Low P.A. Complex regional pain syndrome type I: incidence and prevalence in Olmsted County, a population-based study. Pain 2003, 103:199-207.
30. Sibanc B., Lesnicar G. Complex regional pain syndrome and lyme borreliosis: two different diseases?. Infection 2002, 30:396-399.
31. Tavares Da Silva F., De Keyser F., Lambert P.-H., Robinson W.H., Westhovens R., Sindic C. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine 2013, 31:1870-1876.
32. Van de Beek W.-J.T., Roep B.O., van der Slik A.R., Giphart M.J., van Hilten B.J. Susceptibility loci for complex regional pain syndrome. Pain 2003, 103:93-97.
33. Van de Vusse A.C., Goossens V.J., Kemler M.A., Weber W.E. Screening of patients with complex regional pain syndrome for antecedent infections. Clin J Pain 2001, 17:110-114.
34. Van Eijs F., Stanton-Hicks M., Van Zundert J., et al. Evidence-based interventional pain medicine according to clinical diagnoses. 16. Complex regional pain syndrome. Pain Pract Off J World Inst Pain 2011, 11:70-87.
35. Van Hilten J.J., van de Beek W.J., Roep B.O. Multifocal or generalized tonic dystonia of complex regional pain syndrome: a distinct clinical entity associated with HLA-DR13. Ann Neurol 2000, 48:113-116.
36. Van Holle L., Zeinoun Z., Bauchau V., Verstraeten T. Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study. Pharmacoepidemiol Drug Saf 2012, 21:603-610.
37. Vaneker M., van der Laan L., Allebes W., Goris J. Genetic factors associated with complex regional pain syndrome 1: HLA DRB and TNF alpha promoter gene polymorphism. Disabil Med 2002, 2:69-74.
38. Wasner G. Vasomotor disturbances in complex regional pain syndrome-a review. Pain Med Malden Mass 2010, 11:1267-1273.
39. Wilson R., Paterson P., Larson H. The HPV vaccination in Japan. A Report of the CSIS Global Health Policy Centre 2014, Cent Strateg Int Stud, (published online May. http://csis.org/publication/hpv-vaccination-japan).